UK must act quickly to become world leader in regenerative medicine, MPs hearBMJ 2016; 355 doi: https://doi.org/10.1136/bmj.i5701 (Published 21 October 2016) Cite this as: BMJ 2016;355:i5701
- Adrian O’Dowd
The United Kingdom has to move quickly to become a world class base for regenerative medicine, a rapidly developing science that could lead to groundbreaking new ways of providing care for patients, MPs have been told.
The window of opportunity for the UK to be a global centre for this kind of research and medicine—which includes cell therapy, gene therapy, and tissue engineering—is narrow, experts told MPs on the House of Commons science and technology committee during an evidence session on 19 October for its inquiry into regenerative medicine.
Time constraints were highlighted by one witness, Ian McCubbin, an employee of GlaxoSmithKline and co-chair of the Advanced Therapy Manufacturing task force, which is set to publish an action plan next month to anchor advanced therapy commercial …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial